News INOVIO reports FDA partial clinical hold for planned phase II /III trial of COVID-19 vaccine candidate INO 4800.

INOVIO announced that the FDA has notified the company it has additional questions about the company's planned Phase II/III trial of its COVID-19 vaccine candidate INO 4800, including its Cellectra 2000 delivery device to be used in the trial.